122 related articles for article (PubMed ID: 24409595)
1. The future of oncology treatment through diagnostic testing.
Oakley G
MLO Med Lab Obs; 2013 Dec; 45(12):38. PubMed ID: 24409595
[No Abstract] [Full Text] [Related]
2. [Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: strategies and challenges].
Herth FJ; Bubendorf L; Gütz S; Morresi-Hauf A; Hummel M; Junker K; Lehmann U; Petersen I; Schnabel PA; Warth A
Pneumologie; 2013 Apr; 67(4):198-204. PubMed ID: 23576199
[TBL] [Abstract][Full Text] [Related]
3. Personalized therapy for non-small cell lung cancer: hype or clinical reality?
Wigle DA
Semin Thorac Cardiovasc Surg; 2011; 23(1):30-5. PubMed ID: 21807296
[No Abstract] [Full Text] [Related]
4. First-line therapy of mutated non-small cell lung cancer: an update.
Stöhlmacher-Williams J
Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
[TBL] [Abstract][Full Text] [Related]
5. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
[No Abstract] [Full Text] [Related]
6. The tissue is the issue: personalized medicine for non-small cell lung cancer.
Hirsch FR; Wynes MW; Gandara DR; Bunn PA
Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
[TBL] [Abstract][Full Text] [Related]
7. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
8. [Molecular targeted therapies and cytotoxics: Friends or foes?].
Vignot S; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
[No Abstract] [Full Text] [Related]
9. Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC).
Nellesen D; Dea K; Guerin A; Culver KW; Mutebi A; Dalal A
Am J Manag Care; 2018 Feb; 24(2 Spec No.):SP37-SP42. PubMed ID: 29689141
[No Abstract] [Full Text] [Related]
10. "Personalizing" therapy for non-small cell lung cancer.
D'Cunha J
Semin Thorac Cardiovasc Surg; 2010; 22(2):118-20. PubMed ID: 21092888
[TBL] [Abstract][Full Text] [Related]
11. Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie.
Evans M; Summers Y; Taylor P; Harris M; Bayman N; Faivre-Finn C; Sheikh H; Burt P; Blackhall F; Califano R
Lung Cancer; 2013 Dec; 82(3):510-1. PubMed ID: 24138902
[No Abstract] [Full Text] [Related]
12. Lung cancer in 2014: optimizing lung cancer treatment approaches.
Rosell R; Karachaliou N
Nat Rev Clin Oncol; 2015 Feb; 12(2):75-6. PubMed ID: 25533943
[TBL] [Abstract][Full Text] [Related]
13. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
[No Abstract] [Full Text] [Related]
14. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
Reck M; Rabe KF
N Engl J Med; 2017 Aug; 377(9):849-861. PubMed ID: 28854088
[No Abstract] [Full Text] [Related]
15. Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?
Booton R; Blackhall F; Kerr K
Thorax; 2011 Apr; 66(4):273-5. PubMed ID: 21345972
[No Abstract] [Full Text] [Related]
16. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
[TBL] [Abstract][Full Text] [Related]
17. [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].
Greillier L; Barlesi F
Rev Mal Respir; 2012 Jan; 29(1):4-6. PubMed ID: 22240212
[No Abstract] [Full Text] [Related]
18. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
19. Tissue sampling in lung cancer: a review in light of the MERIT experience.
Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Heigener DF; Reck M
Adv Ther; 2011 Feb; 28(2):126-33. PubMed ID: 21181318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
